Cocoon worked with a world leader in mRNA vaccine research and production to produce a key enzyme in its manufacturing process at a >70% cost reduction.

Visit our product page

The challenge – barriers to production

The enzyme of interest, a thermostable inorganic pyrophosphatase, plays a critical role of eliminating phosphate byproducts in the in vitro transcription (IVT) for mRNA synthesis, an important step in the production of mRNA vaccines. Our client, based in Europe, needed to guarantee a reliable supply of this critical enzyme, that would not be affected by current geopolitical fluctuations impacting on the final cost of the product. Added to that, our proprietary expression system is flexible enough to achieve the maximum range of affordability which translates into unlocking access of advanced therapies for patients.

The solution – a novel expression system

Serving globally from the heart of Spain, from our GMP compliant facility and using our CrisBio® platform, our clients are enabled to use enzymes of the highest quality comparable to gold standards, and at the same time,  significantly reduce the cost and risk of the critical high-value enzyme’s supply for mRNA vaccines, and therapeutics research and production.

CrisBio® is Cocoon’s novel protein expression system. It’s an automated platform that transforms insects in their chrysalis stage into natural bioreactors producing recombinant proteins.

Using these natural and easily scalable bioreactors, CrisBio® vastly reduces operational costs while also improving successful expression rates to reduce the overall cost of enzyme production.

Discover more about our technology

We quickly produced a sample of TIPP with high performance, while meeting all the necessary quality testing controls. Most importantly, by producing pyrophosphatase below prevailing market costs, we enabled expanded access to the enzyme, facilitating continued research and advancement toward the next phase of development.

The results – highly competitive pricing

A cost reduction of more than 70%

Performance equal to a leading enzyme producer 

The future – supporting more applications for pyrophosphatase

We have seen significant demand for pyrophosphatase beyond only mRNA synthesis. Representing one of the most utilized enzymes in terms of volume, keeping production costs to a minimum is essential for current and future scientific development of advanced therapies.

If you are interested in working with us to lower your TIPP costs or have any custom requirements, get in touch.